Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a note issued to investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

BLPH opened at $0.06 on Monday. Bellerophon Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $11.15. The firm has a market capitalization of $716,678.00, a PE ratio of -0.07 and a beta of 0.67. The company’s 50-day moving average is $0.05 and its 200 day moving average is $0.06.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.